SCHEMBL4575185

SCHEMBL4575185

Cc1ccc(C2(c3noc(CN4CCC(NS(=O)(=O)c5ccccc5)CC4)n3)CCCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 2/20 0.57
MAPT P10636 2/20 0.57
HTT P42858 2/20 0.55
HTR1A P08908 2/20 0.43
HTR7 P34969 2/20 0.43
RBP1 P09455 3/20 0.43
CCR3 P51677 1/20 0.42
MCOLN2 Q8IZK6 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
MCOLN1 Q9GZU1 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8223152 0.99 KMT2A (0.60) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL4574665 0.96 KMT2A (0.55) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL4574616 0.94 KMT2A (0.50) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL8226396 0.93 KMT2A (0.51) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL8220554 0.91 CCR3 (0.52) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL8224526 0.87 CCR3 (0.53) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL4575246 0.87 HTT (0.57) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL8221253 0.87 KMT2A (0.47) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL4575547 0.80 KMT2A (0.72) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL8220788 0.76 KMT2A (0.64) KMT2AMEN1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008050200-A1 OXADIAZOLE COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS PFIZER PRODUCTS INC. (US) 2008-05-02 WO claimed
WO-2008050200-A1 OXADIAZOLE COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS PFIZER PRODUCTS INC. (US) 2008-05-02 WO disclosed